Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
24/06/2025 12:14
June 24 (Reuters) - Royalty Pharma RPRX.O said on Tuesday will pay up to $2 billion to Revolution Medicines RVMD.O to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib. (Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)